Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE